An2 Therapeutics, Inc. ANTX
Institutional shares held
13.5 Million
0
calls
0
puts
Total value of holdings
$20.3M
$0
calls
$0
puts
Market Cap
$29.1M
19,402,700
Shares Out.
Institutional ownership
69.81%
# of Institutions
33
We take great care to ensure that the data presented and summarized in this overview for AN2 Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ANTX
View all-
Bml Capital Management, LLC Zionsville, IN5.75MShares$8.62 Million3.62% of portfolio
-
Ra Capital Management, L.P. Boston, MA2MShares$3 Million0.03% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA1.56MShares$2.33 Million0.22% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.04MShares$1.56 Million0.0% of portfolio
-
Acuitas Investments, LLC446KShares$668,6740.23% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny424KShares$635,7000.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny398KShares$596,8870.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA313KShares$468,9220.0% of portfolio
-
Black Rock Inc. New York, NY300KShares$449,5540.0% of portfolio
-
Geode Capital Management, LLC Boston, MA220KShares$330,2430.0% of portfolio
Latest Institutional Activity in ANTX
Top Purchases
Top Sells
About ANTX
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Insider Transactions at ANTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 10
2024
|
Robin Shane Readnour |
BUY
Open market or private purchase
|
Indirect |
10,000
+0.81%
|
$10,000
$1.49 P/Share
|
|
Dec 09
2024
|
Robin Shane Readnour |
BUY
Open market or private purchase
|
Indirect |
30,772
+2.43%
|
$30,772
$1.43 P/Share
|
|
Dec 06
2024
|
Robin Shane Readnour |
BUY
Open market or private purchase
|
Indirect |
19,228
+1.61%
|
$19,228
$1.45 P/Share
|
|
Nov 27
2024
|
Robin Shane Readnour |
BUY
Open market or private purchase
|
Indirect |
50,000
+4.1%
|
$50,000
$1.42 P/Share
|
|
Nov 27
2024
|
Joseph S Zakrzewski |
BUY
Open market or private purchase
|
Direct |
2,000
+1.57%
|
$2,000
$1.4 P/Share
|
|
Nov 26
2024
|
Robin Shane Readnour |
BUY
Open market or private purchase
|
Indirect |
25,000
+2.18%
|
$25,000
$1.39 P/Share
|
|
Nov 20
2024
|
Robin Shane Readnour |
BUY
Open market or private purchase
|
Indirect |
50,000
+4.36%
|
$50,000
$1.16 P/Share
|
|
Nov 19
2024
|
Robin Shane Readnour |
BUY
Open market or private purchase
|
Indirect |
150,000
+12.54%
|
$150,000
$1.04 P/Share
|
|
Nov 19
2024
|
Joseph S Zakrzewski |
BUY
Open market or private purchase
|
Direct |
5,000
+3.9%
|
$5,000
$1.01 P/Share
|
|
Nov 18
2024
|
Joseph S Zakrzewski |
BUY
Open market or private purchase
|
Direct |
20,000
+14.47%
|
$20,000
$1.0 P/Share
|
|
Nov 18
2024
|
Eric Easom Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
50,000
+4.48%
|
$50,000
$1.0 P/Share
|
|
Nov 04
2024
|
Stephen David Prior Chief Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,125
+22.27%
|
-
|
|
Nov 04
2024
|
Joshua M Eizen |
BUY
Grant, award, or other acquisition
|
Direct |
31,500
+19.96%
|
-
|
|
Aug 14
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
1,500,000
+20.69%
|
$1,500,000
$1.04 P/Share
|
|
Aug 09
2024
|
Ra Capital Management, L.P. |
SELL
Open market or private sale
|
Indirect |
3,525,094
-47.01%
|
$3,525,094
$1.08 P/Share
|
|
Jul 10
2024
|
Joshua M Eizen |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+38.75%
|
-
|
|
Mar 15
2024
|
Eric Easom Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
99,000
+49.47%
|
-
|
|
Mar 15
2024
|
Paul Eckburg Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+36.85%
|
-
|
|
Mar 15
2024
|
Sanjay Chanda Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,500
+49.34%
|
-
|
|
Mar 15
2024
|
Kevin Michael Krause Chief Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+48.45%
|
-
|
Last 12 Months Summary
Buy / Acquisition
2.27M
Shares
From
12
Insiders
| Open market or private purchase | 1.91M shares |
|---|---|
| Grant, award, or other acquisition | 346K shares |
| Exercise of conversion of derivative security | 10K shares |
Sell / Disposition
3.84M
Shares
From
7
Insiders
| Open market or private sale | 3.84M shares |
|---|